



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Afinitor

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Form with fields for Patient Name, Member/Subscriber Number, Date of Birth, Group Number, Address, City, State ZIP, Primary Phone, Prescriber Name, Supervising Physician, Fax, Office Contact, NPI, Address, City, State ZIP, Specialty/facility name, and State Lic ID.

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. What diagnosis is this drug being prescribed for (pick one)?
Q2. If you selected "other" in question 1, please provide documentation that use is consistent with a category 2A or higher recommendation per NCCN compendia or guidelines.
Q3. Please provide ICD code(s) for diagnosis.
Q4. Please indicate location of administration.



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Afinitor

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
	Supervising Physician:
<input type="checkbox"/> Physician office (drug from office stock - buy and bill) <input type="checkbox"/> Physician office (drug from pharmacy with a prescription)	
Q5. Is the prescribing physician an Oncologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q6. If RCC: Has the patient demonstrated disease progression or intolerance following treatment with Sutent (sunitinib) or Nexavar (sorafenib)? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. If SEGA: Is the patient a candidate for surgical resection? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. If PNET or NET: Is the tumor unresectable, locally advanced, or metastatic? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. If breast cancer: Is the patient a postmenopausal woman? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q10. If breast cancer: Is Afinitor being used in combination with exemestane? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q11. If breast cancer: Has the patient failed treatment with letrozole or anastrozole? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q12. If renal angiomyolipoma and tuberous sclerosis complex (TSC): Does the patient require immediate surgery? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q13. Additional Comments	



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Afinitor

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:
----------------------	--

Prescriber Signature

Date

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document